Exelixis EV/EBIT EXEL

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2012.

Today, Oct 23, 2026: 15.4×
9-year median: 16.3×
Against its 9-year history: 48th; percentile: 0 is its lowest day, 100 its highest
9-year range: 9.6× to 189×
Peer median: 24.0×

Exelixis' EV/EBIT is 15.4× as of Oct 23, 2026.

That is below its 9-year median of 16.3×, close to the middle of its last 9 years.

Over that time it ranged from 9.6× in Dec 2022 to 189× in Jul 2017.

The median for 10 biotech stocks of a similar size is 24.0×.

EV/EBIT over time

median 16.3×

The dashed line is the 9-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	15.4×	11.0×	15.4×
2025	14.1×	12.2×	14.7×
2024	13.6×	12.5×	23.3×
2023	24.1×	10.2×	24.1×
2022	9.8×	9.6×	24.9×
2021	22.8×	18.8×	131×
2020	31.2×	10.4×	32.4×
2019	11.8×	10.0×	17.8×
2018	14.2×	11.9×	53.7×
2017	51.5×	43.5×	189×
2016	n/m a value too high to mean anything
2015	n/m a value too high to mean anything
2014	n/m a value too high to mean anything
2013	n/m a value too high to mean anything
2012	6.5×	4.6×	8.2×

Against its peers

Companies in Biotechnology nearest Exelixis' size, closest first, today.

Company	EV/EBIT
EXELExelixis	15.4×
NBIXNeurocrine Biosciences	18.2×
HALOHalozyme Therapeutics	17.4×
TECHBIO-TECHNE	44.9×
INCYIncyte	10.1×
UTHRUnited Therapeutics	16.1×
RGENRepligen	160×
KRYSKrystal Biotech	42.4×
ALNYAlnylam Pharmaceuticals	27.9×
ONCBeOne Medicines	42.2×
REGNRegeneron Pharmaceuticals	20.0×
Peer median	24.0×

Where Exelixis ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Exelixis

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.